A study has observed a rise in the number of new cases of myeloma in both men and women in the U.S. since the turn of the century, with the steepest increases seen among young Hispanic women. The incidence, or number of new cases diagnosed each year, of myeloma…
Read more
When added to a second-line combination therapy, Blenrep (belantamab mafodotin) — developed by GlaxoSmithKline (GSK) for relapsed or treatment-resistant multiple myeloma — works better than Darzalex (daratumumab) at significantly delaying disease progression or death among…
The U.S. Food and Drug Administration (FDA) is delaying its review of an application that seeks to allow the cell therapy Abecma (idecabtagene vicleucel) to be used earlier in the treatment of difficult-to-manage multiple myeloma. Abecma currently is FDA-approved for adults with relapsed or refractory multiple myeloma (RRMM) who…
Myeloma is a cancer that forms from a type of white blood cell called B-cells. Learn more about the disease here.
Mutations in critical oncogenes or tumor suppressor genes in B-cells can cause myeloma. Learn more about the causes here.
Symptoms vary from patient to patient and may be mild in the early stages. Learn more about the symptoms here.
Get regular updates to your inbox.
